Evidence map›Paper›PMID 35839317›Full record

ArticleClinical and translational medicine2022

UBQLN4 promotes STING proteasomal degradation during cisplatin-induced DNA damage in triple-negative breast cancer.

Yoshiaki Shoji, Takamichi Yokoe, Yuta Kobayashi, Tomohiro Murakami, Peter J Bostick, Yosef Shiloh, Dave S B Hoon, Matias A Bustos

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Cells · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yoshiaki ShojiDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, California, USA.
Takamichi YokoeDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, California, USA.
Yuta KobayashiDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, California, USA.
Tomohiro MurakamiDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, California, USA.
Peter J BostickMayo Clinic Care Network, Baton Rouge General Medical Center, Baton Rouge, Louisiana, USA.
Yosef ShilohDavid and Inez Myers Laboratory for Cancer Genetics, Tel Aviv University School of Medicine, Tel Aviv, Israel.
Dave S B HoonDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, California, USA.ORCID 0000-0003-1915-3683
Matias A BustosDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, California, USA.
Saint John's Health Center · USBaton Rouge General · USTel Aviv University · IL

Funding

Multiphoton Microscope for Deep Tissue ImagingS10OD025017 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENTOLILA, LAURENT A. · 2018 to 2018
$599k
NIH HHS S10 OD025017
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CisplatinTriple Negative Breast NeoplasmsCarrier ProteinsDNA DamageHumansNuclear ProteinsCarrier ProteinsCisplatinNuclear ProteinsUBQLN4 protein, human

Identifiers

PMID35839317
PMCPMC9286529
OpenAlexW4285499710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.